mTORC1 Inhibition Reduced Survival in Short-Telomere Mice
In telomerase-deficient mice with critically short telomeres, rapamycin or loss of S6 kinase 1 reduced survival, supporting the hypothesis that elevated mTOR activity helps survival in this model.
In mice with critically short telomeres, inhibiting mTORC1 reduced survival.
The finding comes from telomerase-deficient mice. The mTOR signaling pathway regulates cell growth, protein synthesis, and autophagy. Activity of mTORC1, a complex involved in this pathway, was elevated in the liver, skeletal muscle, and heart.
Rapamycin, which inhibits mTORC1, or loss of S6 kinase 1 (S6K1), which acts downstream in the pathway, reduced mouse survival. Elevated mTOR activity may help these mice survive with critically short telomeres. This is a hypothesis: the available evidence does not explain how such compensation would work.
Maria Blasco studies how telomeres shape aging, cancer, and regeneration. The available evidence does not specify her contribution to this experiment. The result concerns a particular mouse model; whether it applies to humans is unknown. These data therefore do not support a general conclusion that mTOR inhibition is harmful.
This edge links Maria Blasco’s telomere research to a specific result that complicates broad claims about mTOR inhibition, while keeping the missing mechanism and human relevance explicit.